This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Mirtazapine for insomnia

Authoring team

A study found low-dose mirtazapine (7.5 mg to 15 mg per day) provided a statistically significant and clinically relevant reduction of insomnia severity at 6 weeks vs. placebo but not at later time points, whereas for low-dose amitriptyline, the reduction was statistically, but not clinically relevant (1):

  • low doses of the antidepressants amitriptyline and mirtazapine are widely prescribed as an alternative treatment when there is a need for sleep medication that can be used for several months
    • intervention consisted of a 16-week daily intake of either one or two tablets of mirtazapine 7.5 mg, amitriptyline 10 mg, or placebo
    • patients were instructed to start with one tablet per night, taken 2 hours to 30 minutes before bedtime
  • demonstrates a statistically significant and clinically relevant effect of low-dose mirtazapine (7.5-15mg/day) on insomnia severity at 6 weeks, but not at 12 weeks during treatment nor at follow-up up to 12 months

In this "...placebo-controlled study in 80 patients with insomnia disorder in general practice demonstrated a statistically significant and clinically relevant effect of low-dose mirtazapine (7.5–15 mg/day) on insomnia severity at 6 weeks, but not at 12 weeks during treatment or at follow-up to 12 months. Secondary sleep outcomes ....supported effectiveness of low-dose mirtazapine up to at least 6 weeks. Side effects and discontinuation due to side effects were more common in the mirtazapine group compared with placebo, suggesting lower tolerability. However, this last difference was not statistically significant.

Low-dose amitriptyline (10–20 mg/day) resulted in a statistically significant reduction in insomnia severity at week 6 only, which was smaller than clinically relevant. There were no statistically significant and clinically relevant improvements on secondary outcomes for amitriptyline during treatment or follow-up to 12 months. Amitriptyline was tolerated well..."

Reference:

  1. Bakker M et al. Effectiveness of low-dose amitriptyline and mirtazapine in patients with insomnia disorder with sleep maintenance problems: a randomised, double-blind, placebo-controlled trial in general practice (DREAMING). BJGP.2024.0173.

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2025 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.